Jul 5, 2024 | Biosimilars, Cost Savings, Humira, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Jun 10, 2024 | Affordable Care Act, Caroline Fraker, MedBen Rx, Obesity, Wegovy, Weight loss, Weight loss drugs, Zepbound
While most health plans do not currently cover obesity medications like Wegovy and Zepbound – and MedBen Rx recommends clients continue not to do so – constant media coverage means the calls to do so will only grow. Therefore, employers are increasingly considering...
May 13, 2024 | Diabetes, Kurt Harden, MedBen Rx, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
Apr 30, 2024 | Alternative Reimbursement Strategies, Biosimilars, Brian Fargus, Brooke Hupp, Caroline Fraker, Fair market reimbursement, Kurt Harden, MedBen Rx, MedBen University, Mental health parity, Municipalities, Nutrigenomics, Pharmacogenomics, Roundtables
At the 18th Annual MedBen University Municipality & Public Employer Roundtable on April 24, clients were shown how MedBen’s self-funding solutions are lowering medical and pharmacy spend while promoting healthier workplaces. Attendees were also introduced to...
Apr 29, 2024 | Access solutions, Alternative Reimbursement Strategies, Benefits preservation, Cost Savings, Direct-to-Employer Contracting, MedBen Rx, Savings, Spousal limitations
It’s hardly shocking that in a new national benefits employer survey, 29 percent of respondents cited “reducing costs” as the most important consideration for employee benefit decisions. However, the steps some employers are using to lower their...
Apr 16, 2024 | Biosimilars, Cost Savings, Drug costs, Humira, MedBen Rx, Pharmacy, Prescription, Rx Costs, Savings
Last year, MedBen Rx announced a new program that would enable clients to purchase Idacio, a biosimilar version of the anti-inflammatory therapy Humira – a drug that typically costs between $6,000 and $12,000 per month depending on the dose – for under $1,000 per...
